Status:
UNKNOWN
Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO)
Lead Sponsor:
Dongfang Hospital Beijing University of Chinese Medicine
Conditions:
Pulmonary Lesions
Eligibility:
All Genders
20-80 years
Phase:
PHASE3
Brief Summary
With the advent of CT screening for lung cancer, there is an increase in the detection of pulmonary lesions with focal pure ground-glass opacity (pGGO). The pure Ground-glass opacities can be caused b...
Eligibility Criteria
Inclusion
- The lesion(s) treated with ablation must be =\< 2.0 cm in greatest dimension
- All patients are required to have been evaluated in a multi-disciplinary tumor conference to ensure that the lesion is suitable for Image-guided percutaneous ablation
- Platelet count ≥ 100 x 109/L
- International normalized ratio (INR) \< 1.5
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- A signed study specific consent form is required
Exclusion
- Direct evidence of regional or distant metastases,or synchronous primary or prior malignancy in the past 5 years
- Unable to lie flat or has respiratory distress at rest
- Uncontrolled coagulopathy or bleeding disorders
- Evidence of active systemic, pulmonary, or pericardial infection
- Women who are pregnant or breastfeeding
- Patients with poor pulmonary function
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2014
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01429649
Start Date
September 1 2011
End Date
December 1 2014
Last Update
September 7 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dongfang Hospital
Fuzhou, Fujian, China, 350025